Dermapharm Holding Se · XETR:DMP

Dermapharm — Q3 2021 Earnings Presentation

17 slides from Dermapharm's earnings presentation, Nov 16, 2021

  1. Slide 1: Investor and Analyst Conference Call Q3 2021

    INVESTOR AND ANALYST CONFERENCE CALL Q3 2021 Grünwald, 16 November 2021

  2. Slide 2: Disclaimer

    Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward- Looking Sta

  3. Slide 3: Agenda

    AGENDA 1. Highlights Q3 2021 2. Financial figures Q3 2021 3. Outlook FY 2021 4. Q & A

  4. Slide 4: Agenda: Highlights Q3 2021

    AGENDA 1. Highlights Q3 2021 2. Financial figures Q3 2021 3. Outlook FY 2021 4. Q & A

  5. Slide 5: Highlights 9M 2021

    Highlights 9M 2021 Dermapharm continues its successful growth course Vaccine production Ongoing vaccine production in Brehna and Reinbek – investment in production equipment for “fill & finish” in Brehna Strengthening of segment Herbal Extracts Acquisition of AB Cernelle, a Swedish manufacturer of a

  6. Slide 6: Agenda: Financial figures Q3 2021

    AGENDA 1. Highlights Q3 2021 2. Financial figures Q3 2021 3. Outlook FY 2021 4. Q & A

  7. Slide 7: Dermapharm Group

    Dermapharm Group Continuous growth, while COVID-19 pandemic slowed down Total Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin +16.1% YoY 24.1% 34.0% 670.2 Significant revenue growth of 16.1% to €670.2m, due to 577.2  vaccine production in cooperation with BioNTech SE  revenue contribu

  8. Slide 8: Branded pharmaceuticals and other healthcare products

    Branded pharmaceuticals and other healthcare products Strong growth contribution from vaccine, Allergopharma and vitamines Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin +32.6% YoY 37.4% 48.8% Revenues up by 32.6% to €440.1m  full 9M period contribution of Allergopharma  substantial

  9. Slide 9: Herbal extracts

    Herbal extracts Global demand for herbal extracts remains stable Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin -2.0% YoY 23.0% 28.9% Revenues decreased by 2.0% to €54.6m, comprising Euromed  stable global demand led to constant sales volume, while revenue was negatively impacted by F

  10. Slide 10: Parallel import business

    Parallel import business Declining market and regulatory changes impact results Revenue (€m) EBITDA (€m) Comments EBITDA Margin -7.5% YoY 3.3% 1.3% Revenues decreased by 7.5% to €175.4m  PI market decline due to reduced demands  growth in direct traded OTC, narcotics and medical cannabis could not

  11. Slide 11: Earnings before tax (Group EBT)

    Earnings before tax (Group EBT) Result increased due to vaccine production and M&A Earnings before tax (EBT)(1) (€m) Comments EBT Margin 15.6% 28.6%  EBT increased by 112.0% to €191.4m (unadjusted) resulting in a margin of 28.6% Mainly influenced by +111.9% YoY  disproportional increase of depreci

  12. Slide 12: Strong operating cash flows and cash conversion

    Strong operating cash flows and cash conversion Cash flow and cash conversion(1) (€m) Comments in % of Group EBITDA Cash conversion 47.8% 63.2%  CF from operating activities increased, mainly influenced by increased EBT in 9M 2021  CF from investing activities has almost remained at the same level

  13. Slide 13: Balance sheet of Dermapharm Group

    Balance sheet of Dermapharm Group Balance Sheet as of 30 September 2021 (€m) Comments 1,340 1,340 (2)  Total assets increased to €1,340m (31 December 2020: €1,224m)  Non-current assets increased to €878m (31 December 2020: €824m) Equity  Current assets increased to €462m 426 (31 December 2020: €4

  14. Slide 14: Agenda: Outlook FY 2021

    AGENDA 1. Highlights Q3 2021 2. Financial figures Q3 2021 3. Outlook FY 2021 4. Q & A

  15. Slide 15: Growth strategy - adjusted guidance 2021

    Growth strategy - adjusted guidance 2021 Revenues 2021 positive growth of 15-20% vs. previous year (€793.8m) EBITDA 2021 positive growth of 50-60% (adjusted) vs. previous year (€200.7m) Based on the Q3 development we adjust the guidance given for 2021. Due to the declining demand in the segment “par

  16. Slide 16: Agenda: Q & A

    AGENDA 1. Highlights Q3 2021 2. Financial figures Q3 2021 3. Outlook FY 2021 4. Q & A

  17. Slide 17: Investor contact

    Investor contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233

Dermapharm Holding — Q3 2021 Earnings Presentation on 6ix